Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions

• Published in: Hematological oncology 2013-06, Vol.31 (2), p.72-78
• Main Authors: Falorio, Simona, Biasoli, Irene, Luminari, Stefano, Quintana, Giovanni, Musso, Maurizio, Dell'Olio, Matteo, Specchia, Maria Rosaria, di Renzo, Nicola, Cesaretti, Marina, Buda, Gabriele, Vallisa, Daniele, Mannina, Donato, Andriani, Alessandro, Chiattone, Carlos Sérgio, Delamain, Márcia Torresan, de Souza, Cármino A, Spector, Nelson, Angrilli, Francesco, Federico, Massimo
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Brazil; Contraceptives, Oral; Female; fertility; Fertility Preservation; GnRH-a; Hodgkin Disease - physiopathology; Hodgkin Disease - therapy; Hodgkin lymphoma; Humans; Infertility - etiology; Italy; Ovary - physiopathology; Retrospective Studies; Risk Factors; Survival Analysis; survivors; Young Adult
• ISSN: 0278-0232; 1099-1069
• DOI: 10.1002/hon.2029

Hodgkin lymphoma (HL) is one of the most common types of cancer in the young and one of the most curable forms of cancer. Therefore, there has been an increasing interest in the study of long‐term morbidities. The aims of the present study were to evaluate the prevalence and risk factors for impaired gonadal function in a retrospective cohort of 238 HL female survivors from Italy and Brazil and to analyse the role of oral contraceptives (OC) and GnRH‐analogues. Besides data collection from HL databases, a specific questionnaire was administered to collect data on gonadal function. The median age at diagnosis was 25 years and the median follow‐up was 7 years. Overall, 25% of the patients developed impaired gonadal function. Older age at diagnosis, front‐line therapies containing alkylating agents and more than one treatment were independent risk factors, whereas the use of OC or GnRH‐a reduced independently the risk of impaired gonadal function. The fertility rate among fertile survivors was low when compared with the general population. We confirmed that older age, type of front‐line chemotherapy and a higher number of therapies are associated with gonadal function impairment in terms of infertility and premature menopause in female HL survivors. Also, the use of GnRH‐a or OC was independently identified as a protective factor. Further prospective studies are needed to better understand the barriers to parenthood in HL survivors. Copyright © 2012 John Wiley & Sons, Ltd.